Clinical trial
Durvalumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
NCT02966587
Study timeline
Study start (estimated)2018-05-15Date precision: day
Registry last updated2018-01-17
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Castration Levels of Testosteroneunresolved
Hormone-Resistant Prostate Cancerunresolved
Microsatellite Instabilityunresolved
Interventions
DurvalumabBIOLOGICAL
Sponsors & collaborators
University of Washingtonlead sponsor
National Cancer Institute (NCI)collaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT02966587 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.